NICE rejects Roche's Tecentriq in new lung cancer use

NICE has said in first draft guidance that Roche’s Tecentriq should not get regular NHS funding as a treatment for a kind of advanced lung cancer, citing “highly uncertain” data about the d

Roche snaps up ex-US rights to Sarepta's DMD gene therapy

Roche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar deal.

2019: the year of the pharma mega-merger

2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year that changed the landscape of big pharma

Amgen, Allergan join Rituxan biosimilar challenge with FDA f...

Scotland's NHS to fund Roche's Hemlibra in haemophilia A

NHS patients in Scotland with haemophilia A are set to get access to Roche and Chugai’s prophylactic injection Hemlibra after officials said it was cost-effective.

Novartis top of pile in European pharma in 2020, say Jefferi...

Jefferies’ team of analysts have recently been touting Roche as their favourite big European pharma – but going into 2020 it’s Novartis that gets the strongest “buy” rating in a broker note